
Weight-loss drugs helped fuel nearly $800 million in losses for two biggest Mass. health insurers last year
Both insurers cited rapidly growing costs for a broad range of medical care and medications. But the largest driver was the popularity of the expensive GLP-1 drugs used to treat diabetes and obesity. Costs for five of those drugs — Ozempic, Mounjaro, …